29 Background: Routine identification of fungal pathogens from positive blood cultures by culture-30 based methods can be time consuming, delaying treatment with appropriate antifungal agents. 31 The GenMark Dx ePlex ® Investigational Use Only Blood Culture Identification Fungal Pathogen 32 Panel (BCID-FP) rapidly detects 15 fungal targets simultaneously in blood culture samples 33 positive for fungi by Gram stain. We aimed to determine the performance of the BCID-FP in a 34 multi-center clinical study. 35 Materials and Methods: Blood culture samples collected at 10 US sites and tested with BCID-36 FP at 4 sites were compared to the standard-of-care microbiological and biochemical techniques, 37 PNA-FISH and MALDI-TOF MS. Discrepant results were analyzed by bi-directional 38 PCR/sequencing of residual blood culture samples. 39 Results: A total of 866 clinical samples, 120 retrospectively-and 21 prospectively-collected, 40 along with 725 contrived samples were evaluated. Sensitivity and specificity of the Candida 41 species (C. albicans, C. auris, C. dubliniensis, C. famata, C. glabrata, C. guilliermondii, C, 42 kefyr, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis), ranged from 97.1-100% and 99.8-43 100%, respectively. For the other organism targets, sensitivity and specificity were as follows: 44 100% each for Cryptococcus neoformans and C. gattii, 98.6% and 100% for Fusarium spp. and 45 96.2% and 99.9% for Rhodotorula spp. respectively. In 4 of the 141 clinical samples, the BCID-46 FP Panel correctly identified an additional Candida species, undetected by standard-of-care 47 methods. 48 3 Conclusion: The BCID-FP Panel offers a faster turnaround time for identification of fungal 49 pathogens in positive blood cultures that may allow for earlier antifungal interventions and, 50 includes C. auris, a highly multi-drug resistant fungus. 51 52
Introduction 53
Fungemia is a severe form of systemic and invasive fungal infection and delayed diagnosis of 54 fungal bloodstream infections can result in significant increases in mortality. Candidemia, in 55 particular, is one of the leading causes of bloodstream infections in hospital settings with a crude 56 mortality rate of 40-75% (1). Previously, a multi-center study has shown that the mortality rate 57 significantly increased for every hour delayed in diagnosis of candidemia (2). Rapid diagnosis of 58 candidemia is even more crucial in immunocompromised patient populations because of a higher 59 mortality rate in this patient group (3, 4) . Conventional culture-based identification methods lack 60 the speed needed to aid in choosing the appropriate antifungal drugs for timely management of 61 patients suffering from these invasive fungal infections. 62 Three commercially available molecular tools have been applied to rapidly identify 63 Candida spp. directly from positive blood culture bottles (without waiting for the growth of the 64 organisms on the subsequent culture media): the Candida PNA FISH ® assay (OpGen ® ) (5, 6), 65 the BioFire ® FilmArray ® Blood Culture Identification Panel (BioMerieux ® ) (7), and PhenoTest ® 66 Blood Culture kit (Accelerate Diagnostics) (8). One major limitation of each method is the lack 67 of broad coverage for fungal pathogen detection since the former two methods only target five 68
Candida species: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and the latter 69 one only targets two Candida species: C. albicans and C. glabrata. 70
The ePlex ® Investigational Use Only (IUO) Blood Culture Identification Fungal 71
Pathogen (BCID-FP) Panel (GenMark Dx) is a fully automated one-step test to detect and 72 identify 15 fungal pathogens directly from positive blood cultures. In this study, we conducted a 73 multi-center evaluation to determine the clinical sensitivity and specificity of the ePlex IUO 74 5 BCID-FP Panel for the rapid detection and identification of fungal pathogens directly from 75 positive blood cultures. 76 77 78
MATERIALS AND METHODS 79

Study design and samples 80
Positive blood cultures from patients of all ages and genders were collected at 10 hospitals and 81 medical centers from the following 9 cities located in the U.S.: Albuquerque, New Mexico; 82 Baltimore, Maryland; Charleston, South Carolina; Danville, Pennsylvania; Detroit, Michigan (2 83 sites); Harvey, Illinois; Indianapolis, Indiana; New York City, New York; and San Diego, 84
California. 85
Two sites prospectively collected samples in 2015 and 2016, and 4 sites collected 86 samples from July-August 2018. In addition, samples with gram stain showing fungal organisms 87 were retrospectively collected from 9 sites; they were stored in a freezer (≤-20°C) at the 88 collection sites, and then shipped in frozen condition to the testing laboratory where they were 89 stored in -70°C condition before testing. All prospectively and retrospectively-collected positive 90 blood culture samples were tested by the standard-of-care testing (comparator method) 91 performed at each site as per their standard laboratory procedures. The residual portion of these 92 blood culture samples was de-identified investigated by running molecular assays to determine the presence or absence of the organism 101 directly in residual blood culture samples. The molecular assays employed polymerase chain 102 reaction (PCR) amplification targeting genes associated with each fungal target followed by bi-103 directional sequencing (PCR/sequencing). The molecular assays were validated analytically with 104 precision, limit-of-detection, inclusivity and exclusivity studies using spiked blood culture media 105 and DNA or whole organisms. Descriptions of each gene target, primer sequences and PCR 106 conditions are provided in Supplementary Table 1 . As part of the comparator method, all 107 prospective samples were tested with PCR/sequencing assays to determine the presence/absence 108 of Candida auris, Fusarium (F. dimerum, F. oxysporum, F. Ssacchari, F. solani, F. 109 verticillioides), and Rhodotorula (R. glutinis, R. mucilaginosa) because not all standard-of-care 110 methods may have tested for these organisms initially on a consistent basis. Due to potential 111 misidentification of C. parapsilosis with other cryptic species within the C. parapsilosis species 112 complex, e.g. C. orthopsilosis, C. metapsilosis, by standard of care phenotypic methods (9, 10), 113 samples with Candida parapsilosis identified by standard laboratory procedures were confirmed 114 using the PCR/sequencing assay to determine the comparator method result. 115
Contrived samples were used to establish additional performance metrics for specific 116 fungal targets due to very low prevalence from the prospectively and retrospectively collected 117 7 clinical samples. Each target had contrived samples prepared from at least 3 different strains. 118
Contrived samples were prepared by aseptically injecting 3-10 mL of human whole blood 119 (BioIVT, Westbury, NY) into a BD BacTec blood culture bottle (Plus Aerobic/F, Myco/F Lytic, 120 or Peds Plus/F). The bottles were then inoculated with conidia or spores (in case of Fusarium) 121 from a pure culture of a known organism grown on Sabouraud agar under 30°C between 36 -72 122 hours. The fungal preparation was generated by diluting conidia or spores in saline to 123 approximately 0.5 McFarland via OD 600 reading (0.5 McFarland is equivalent to approximately 124 1.0 x10 6 CFU/mL for yeast cells at OD 600nm ) (11, 12). The fungal preparation was used neat or 125 diluted to either 1:10, 1:100, 1:1000, 1:10000, 1:20000, or 1:100000 and then 100µL (except for 126 two samples used either 400µL or 1mL) was used to inoculate the bottle containing blood. The 127 inoculum was adjusted based on successful growth and time to detection in preliminary 128 samples. The time to detection varied from 11 hours to 5 days for 95% of the contrived samples; 129 the remaining 5% varied from >5 days to 15 days. The contrived sample list is detailed in 130 Supplementary Table 2 . In phase I, 237 samples were collected at 2 sites and frozen for future testing (prospective frozen 175 samples) from May 2015 through July 2016. In phase II, 210 samples were collected at 4 sites 176 from July through August 2018, were never frozen and were tested fresh (prospective fresh 177 samples For prospective subjects, 67% were male and the mean age for this group was 48.1 years 192 old; 71% of the prospective patients ranged in age from 18-64 years old. Among the 193 retrospective subjects, 57% were male and the mean age for this group was 53.5 years old; 55% 194 of these patients ranged in age from 18-64 years ( Supplementary Table 4 ). 195
Ten different blood culture bottle types from 3 manufacturers (BD [Becton Dickinson], 196 bioMérieux Inc, and Thermo Fisher Scientific ® ) were used. The majority of the blood culture 197 bottles used in the prospectively collected samples were BacTec™ PLUS Aerobic/F, in the 198 retrospectively collected samples were BacTec™ PLUS Aerobic/F and BacTec™ Standard/10 199 Aerobic/F, and in the contrived samples were BacTec™ Myco/F Lytic ( Supplementary Table 5 ). Overall, test sensitivity/PPA and specificity/NPA were 100% for the following 6 fungal 211 targets on the BCID-FP Panel: C. auris, C. dubliniensis, C. famata, C. krusei, C. gattii, and C. 212 neoformans. The sensitivity/PPA for the remaining fungal targets ranged from 96.2% to 100%, 213 and specificity/NPA ranged from 99.8% to 100%. A total of 9 false negative results were found 214 in the samples containing the following fungal targets: 5 contrived samples each spiked with C. 215 albicans, C. guilliermondii, Fusarium spp., and Rhodotorula spp. (n=2); 4 retrospectively 216 collected clinical samples each positive for C. albicans, C. glabrata, C. lusitaniae, and C. 217 parapsilosis ( Table 2) . A total of 9 false positive results were detected in the following samples: 218 5 were found to be positive in contrived samples without spiking the following fungal targets for 219 C. albicans, C. kefyr (n=2), C. lusitaniae, and Rhodotorula spp.; 4 were from retrospectively 220 collected clinical samples that were not identified by comparator methods but were detected by 221 the BCID-FP Panel (2 C. glabrata, 1 C. parapsilosis, and 1 C. tropicalis) (Table 3) Case numbers 4-7 were positive for a single fungal target by the comparator methods. The 239 BCID-FP Panel was able to detect not only the single target but also an additional fungal target 240 in each of these 4 cases as described in the previous paragraph. These additional fungal targets 241 were confirmed by PCR/sequencing results, indicating true co-infections detected by the BCID-242 FP Panel (Table 2) Our multicenter study showed that the ePlex BCID-FP Panel exhibited 100% sensitivity 254 and specificity for 6 fungal targets (C. auris, C. dubliniensis, C. famata, C. krusei, C. gattii, and 255 C. neoformans) and a range of sensitivity of 96.2% -100% and specificity of 99.8% -100% for 256 the remaining fungal targets before resolution of discordant results. While the ePlex BCID-FP 257
Panel missed the detection of fungal targets in 5 contrived samples and 4 retrospective clinical 258 samples (Table 2) , the panel did detect additional fungal targets in 4 cases that were missed by 259 the standard-of-care testing, in turn delivering a faster set of complete results to the clinicians 260 responsible for patient management, so that appropriate treatment can be initiated without delay. 261
For example, the standard-of-care tests only detected C. lusitaniae in case numbers 6 and 7 of 262 mixed fungal infections (Table 4 ). The ePlex BCID-FP Panel detected additional C. glabrata in 263 both cases, which could have allowed the more appropriate choice of echinocandin over 264 fluconazole as per current clinical practice guidelines for the management of candidiasis (15). 265 Importantly, it is the only FDA cleared rapid molecular panel that contains C. auris, 266 which is an emerging multi-drug resistant fungal pathogen that has been reported to cause high 267 mortality and nosocomial outbreaks in the hospital settings (16-18) and has recently been added 268 to the CDC's Antimicrobial Resistance Urgent Threat list. Over 60% of patients infected by C. 269 auris developed bloodstream infection with a mortality rate reaching up to 60% (19) . Rapid 270 detection of C. auris in blood cultures can not only result in early initiation of an appropriate 271 antifungal regimen, (i.e., echinocandins due to its high resistance rate to azoles) (19, 20) , but can 272 also help prevent further spread of this nosocomial multi-drug resistant organism in health care 273 facilities. A large, multi-institution outbreak of C. auris highlighted the clinical importance of its 274 rapid identification as transmission occurs primarily among patients with extensive healthcare 275 exposure and much like Clostridioides difficile, C. auris remains viable on inanimate objects for 276 7-14 days, longer in a non-culturable state, contributing to its nosocomial transmission (21) (22) (23) . 277
Although a positive C. auris result has clear epidemiological impact, a negative result for C. 278 auris is also highly valuable as it would help hospital infection control to rule out this 279 nosocomial pathogen due to the BCID-FP Panel's high specificity for this organism. 280
The ePlex BCID-FP Panel contains 2 non-Candida yeasts, Cryptococcus and 281
Rhodotorula. Although bloodstream infection caused by these yeasts are less common than 282
Candida spp. (24, 25) , annually less than 10,000 cases compared to 25,000 cases in the U. S., 283 rapid and accurate detection of these fungi are paramount because they contribute to a higher 284 mortality rate and antifungal regimens are very different from candidemia (26, 27 In summary, the ePlex BCID-FP Panel, which has recently been cleared by FDA, 301 contains the largest breadth of fungal targets and proved to be an accurate, easy-to-use multiplex 302 molecular tool suitable for clinical laboratories to detect common fungal pathogens causing 303 bloodstream infections more rapidly than traditional and conventional microbiological methods. 304 
